Related Experiment Video
Updated: Jun 8, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Organophosphate induced delayed polyneuropathy in man: an overview
Milan Jokanović1, Melita Kosanović, Dejan Brkić
1Faculty of Medicine, University of Nish, Nish, Serbia. milan.jokanovic@gmail.com
Clinical Neurology and Neurosurgery
|October 1, 2010
Summary
Organophosphate-induced delayed polyneuropathy (OPIDP) is a rare neurodegenerative disorder affecting nerves and the spinal cord. This review covers its clinical aspects, causes, and potential treatments.
Area of Science:
- Neuroscience
- Toxicology
- Neurology
Background:
- Organophosphate-induced delayed polyneuropathy (OPIDP) has been documented in humans for approximately 80 years.
- It is a rare neurodegenerative condition resulting from poisoning with specific organophosphorus compounds.
- OPIDP manifests as sensory and motor axon dysfunction in peripheral nerves and the spinal cord.
Purpose of the Study:
- To provide a comprehensive review of organophosphate-induced delayed polyneuropathy (OPIDP) in humans.
- To detail the clinical presentation, pathogenesis, and molecular mechanisms underlying OPIDP.
- To explore potential strategies for the prevention and therapy of OPIDP.
Main Methods:
- Literature review of human cases and scientific studies on OPIDP.
- Analysis of clinical data, pathological findings, and molecular targets.
- Synthesis of information on pathogenesis and therapeutic interventions.
Main Results:
- OPIDP is characterized by delayed onset (2-3 weeks post-exposure) of ataxia and paralysis.
- The primary molecular target implicated in OPIDP is neuropathy target esterase (NTE) in the nervous system.
- The review consolidates current understanding of OPIDP's multifaceted nature.
Conclusions:
- Understanding the clinical features and pathogenesis of OPIDP is crucial for diagnosis and management.
- Neuropathy target esterase (NTE) is central to OPIDP's molecular pathology.
- Further research into prevention and therapy holds promise for mitigating the effects of organophosphate poisoning.
Related Concept Videos
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:26Toxic Reactions: Overview
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...